Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns

Journal of Hepatology

Volumn 26, Issue 6, 1997, Pages 1393-1395

  Honkoop, Pieter ^a   Niesters, Hubert G M ^a   De Man, Robert A M ^a   Osterhaus, Albert D M E ^a   Schalm, Solko W ^a  

^a NONE

Author keywords

Antiviral treatment; Lamivudine; Nucleoside analogues; Viral resistance; Virus hepatitis B; YMDD motif

Indexed keywords

LAMIVUDINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; HEPATITIS B; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 0030875066     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80476-X     Document Type: Article

References (10)

1. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA. 88:1991;8495-8499.
2. De Man RA, Schalm SW, Main J, Thomas HC, Fevery J, Nevens F, Staley H. A dose ranging study to determine the antiviral activity and the safety of lamivudien (2′-deoxy-3′-thiacytidine) in patients with chronic hepatitis B infection. Gut. 34:1993;S5.
3. Dienstag JL, Perrillo RP, Schiff ER, Batholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 333:1995;1657-1661.
4. Nevens F, Tyrell DL, de Man RA, Main J, Beranek P, Sidar S, Fevery J, Schalm SW, Thomas HC. A six months dose ranging study of the safety and efficacy of lamivudine in chronic hepatitis B. J Hepatol. 23:((S1)):1995;91.
5. Schinazi RF, Chu CK, Peck A, McMillan A, Mathis R, Cannon D, et al. Activities of the four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother. 36:1992;672-676.
6. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA, Cameron JM. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 37:1993;2231-2234.
7. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol. 10:1995;S28-S33.
8. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
9. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DLJ. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.
10. de Man RA, Niesters HGM, Fevery J, Main J, Nevens F, Schalm SW, Thomas HC, Tyrrell DL. Evaluation by limiting dilution PCR of HBV-DNA decrease in a double-blind randomised six month trial of lamivudine for chronic hepatitis B: implications for the application in liver transplant recipients. J Hepatol. 23:1995;96.